Evaluation of SARS-CoV-2 Serological Testing in Patients with Multiple Myeloma and Other Hematologic Malignancies on Monoclonal Antibody Therapies
Open Access
- 24 November 2020
- journal article
- research article
- Published by MDPI AG in Diagnostics
- Vol. 10 (12), 992
- https://doi.org/10.3390/diagnostics10120992
Abstract
Background: Patients with hematological malignancies (HM), including multiple myeloma (MM), frequently suffer from immune deficiency-associated infectious complications because of both the disease and the treatment. Alarming results from China and the UK confirm the vulnerability of HM patients to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-driven coronavirus disease 2019 (COVID-19). Given that the immunoassay interference from the endogenous monoclonal immunoglobulin (M paraprotein) and treatment antibodies continually challenges the MM management, it is critical to evaluate the SARS-CoV-2 serology tests for suspected interference/cross-reactivity. Methods: We compared the degree of interference in three SARS-CoV-2 serology assay platforms in HM patients with and without COVID-19 and on various therapeutic monoclonal antibody (t-mAb) treatments. Further, we confirmed the cross-reactivity in pooled samples from normal and COVID-19 + samples spiked with respective antibodies in vitro. Results: None of the 93 HM patient samples with or without t-MAbs showed cross-reactivity on any of the three serology platforms tested. Conclusions: The tested three serologic assays for SARS-CoV-2 are specific and do not have cross-reactivity with M-components or t-MAbs indicating that they can be used safely in oncology practice and in research exploring the immunologic response to COVID-19 in patients with HM.This publication has 12 references indexed in Scilit:
- Diagnostic Performance of a Rapid Point‐of‐care Test for SARS‐CoV‐2 in an Urban Emergency Department SettingAcademic Emergency Medicine, 2020
- COVID-19 mortality in patients with cancer on chemotherapy or other anticancer treatments: a prospective cohort studyThe Lancet, 2020
- Real‐world assessment of the clinical impact of symptomatic infection with severe acute respiratory syndrome coronavirus (COVID‐19 disease) in patients with multiple myeloma receiving systemic anti‐cancer therapyBritish Journal of Haematology, 2020
- Clinical outcome of coronavirus disease 2019 in haemato‐oncology patientsBritish Journal of Haematology, 2020
- Antibody responses to SARS-CoV-2 in patients with COVID-19Nature Medicine, 2020
- Immune Therapies in Multiple MyelomaClinical Cancer Research, 2016
- Role of the Immune Response in Disease Progression and Therapy in Multiple MyelomaPublished by Springer Science and Business Media LLC ,2016
- Monoclonal antibody therapeutics as potential interferences on protein electrophoresis and immunofixationcclm, 2016
- Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patientsHaematologica, 2014
- How paraproteins can affect laboratory assays: spurious results and biological effectsPathology, 2010